english.prescrire.org > Spotlight > Archives : 2024 > Netarsudil (Rhokiinsa°) or netarsudil + latanoprost (Roclanda°) in chronic glaucoma: not acceptable

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2024 : 1 | 30 | 60

Netarsudil (Rhokiinsa°) or netarsudil + latanoprost (Roclanda°) in chronic glaucoma: not acceptable

 Marketing Authorisations   Eye drops containing netarsudil, alone or combined with latanoprost, have been authorised in the European Union to lower intraocular pressure in adults with chronic open-angle glaucoma or ocular hypertension. Netarsudil exposes patients to a higher risk of adverse effects than the first-choice ocular antihypertensive drugs, timolol or latanoprost, while offering no demonstrated gain in efficacy.
Full article available for download by subscribers

©Prescrire 1 July 2024

Source: "Netarsudil (Rhokiinsa°) or netarsudil + latanoprost (Roclanda°) in chronic glaucoma" Prescrire Int 2024; 33 (261): 184-186. Subscribers only.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter
 
See also:

"Timolol + latanoprost:
last resort eye drops"
Prescrire Int 2003;